Psychedelic drugs could one day help treat mental illnesses, but the evidence isn’t strong enough yet to offer them to patients, according to a new report from psychiatrists in the United Kingdom.
After decades of restrictions, researchers have taken a renewed interest in the potential of psychedelics such as MDMA, ketamine, LSD, and psilocybin – the hallucinogenic compound found in magic mushrooms – in recent years. Now, several late-stage clinical trials are ongoing to test psychedelics in the UK, mainland Europe, and the United States.
